Expertise in
43
conditions

Dr. Scott Okuno

Oncology
Mayo Clinic Health System
1221 Whipple St, 
Eau Claire, WI 
Accepting New Patients
Offers Telehealth
Expertise in
43
conditions
Mayo Clinic Health System
1221 Whipple St, 
Eau Claire, WI 

Overview

Scott Okuno is an Oncologist practicing medicine in Eau Claire, Wisconsin.

Dr. Okuno is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Angiosarcoma, and Alveolar Soft Part Sarcoma.

He is actively involved in clinical research, co-authoring 103 peer reviewed articles and participating in 15 clinical trials. Dr. Okuno is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in WI

Hospital Affiliations

Mayo Clinic Health System-Franciscan Medical Center Inc
Mayo Clinic Health System Eau Claire Hospital
Tamarack Health Hayward Medical Center
Mayo Clinic Health System In Red Wing
Mayo Clinic Hospital Rochester

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Sanford Health
  • HMO
  • PPO
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Mayo Clinic Health System
1221 Whipple St, Eau Claire, WI 54703
Other Locations
Mayo Clinic Health System - Eau Claire
1221 Whipple St, Eau Claire, WI 54703
Mayo Clinic Health System - La Crosse
800 West Ave S Fl 1, La Crosse, WI 54601

Additional Areas of Focus

Dr. Okuno has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Enrollment Status: Active_not_recruiting
Publish Date: May 01, 2026
Intervention Type: Other, Drug
Study Drugs: Cabozantinib, Temozolomide
Study Phase: Phase 2
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drug: MDM2 Inhibitor KRT-232
Study Phase: Phase 1
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug
Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas
Enrollment Status: Unknown
Publish Date: November 21, 2023
Intervention Type: Drug
Study Drugs: Seclidemstat, Cyclophosphamide, Topotecan
Study Phase: Phase 1
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Phase 2 Trial of BN-Brachyury and Radiation Therapy in Patients With Advanced Chordoma
A Phase 2 Trial of BN-Brachyury and Radiation Therapy in Patients With Advanced Chordoma
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Biological
Study Drug: BN-Brachyury plus Radiation
Study Phase: Phase 2
Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck or Metastatic Breast Cancer
Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck or Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: February 14, 2023
Intervention Type: Other, Biological
Study Drug: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Study Phase: Phase 1
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

103 Total Publications

ASO Visual Abstract: Improved Oncologic Outcomes with Trimodality Therapy for Radiation-Associated Angiosarcoma of the Breast.
ASO Visual Abstract: Improved Oncologic Outcomes with Trimodality Therapy for Radiation-Associated Angiosarcoma of the Breast.
Journal: Annals of surgical oncology
Published: July 25, 2026
Similar Doctors
Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required

Marshfield Medical Center-Eau Claire Cancer Center

2200 Craig Rd, 
Eau Claire, WI 
 (1.1 miles away)
715-858-6767
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dean Delmastro is an Oncologist practicing medicine in Eau Claire, Wisconsin. Dr. Delmastro is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Hemangioma Thrombocytopenia Syndrome, Inflammatory Breast Cancer, and Pleuropulmonary Blastoma. Dr. Delmastro is currently accepting new patients.

Expertise in
32
conditions
Expertise in
32
conditions
Referral may be required

HSHS Sacred Heart Hospital

900 W Clairemont Ave, 
Eau Claire, WI 
 (1.2 miles away)
715-717-4121
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mihailo Lalich is an Oncologist practicing medicine in Eau Claire, Wisconsin. Dr. Lalich is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), Colorectal Cancer, and Familial Colorectal Cancer. Dr. Lalich is currently accepting new patients.

Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

Marshfield Clinic Chippewa Falls Center-Cancer Care

2655 County Highway I, 
Chippewa Falls, WI 
 (12.2 miles away)
715-726-4200
Languages Spoken:
English, Thai
See accepted insurances
Accepting New Patients
Offers Telehealth

Patcharin Tanawattanacharoen is an Oncologist practicing medicine in Chippewa Falls, Wisconsin. Dr. Tanawattanacharoen is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Inflammatory Breast Cancer, Paget Disease of the Breast, Non-Hodgkin Lymphoma, Thrombocytopenia, and Bone Marrow Aspiration. Dr. Tanawattanacharoen is currently accepting new patients.

Frequently Asked Questions about Dr. Scott Okuno

How do I make an appointment with Dr. Scott Okuno?

You can book an appointment with Dr. Scott Okuno by calling their office at 715-301-0394. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Scott Okuno a top-rated expert for Adult Soft Tissue Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Scott Okuno is classified as an Elite expert for Adult Soft Tissue Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Scott Okuno specialize in?

While Dr. Scott Okuno is a Oncology, they have specific expertise in Adult Soft Tissue Sarcoma, Liposarcoma, and Angiosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Scott Okuno participate in research or clinical trials?

Yes. Dr. Scott Okuno has published 103 articles and abstracts on conditions like Adult Soft Tissue Sarcoma. You can view a list of Dr. Scott Okuno's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Scott Okuno accept my insurance?

Dr. Scott Okuno accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 715-301-0394 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Okuno's expertise for a condition
ConditionClose
View All 14 Distinguished Conditions
View All 23 Advanced Conditions
View All 91 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile